prof. Isabel Leroux-Roels
- Work address
-
C. Heymanslaan 10, ingang 22 - verdieping 2
9000 Gent - Isabel.LerouxRoels@UGent.be
- ORCID iD
-
0000-0002-5084-4696
Show
Sort by
-
- Journal Article
- A1
- open access
Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults : phase 1/2 randomized clinical trial
-
- Journal Article
- A1
- open access
Human immunity and susceptibility to influenza A(H3) viruses of avian, equine, and swine origin
-
Respiratory syncytial virus prefusion F protein vaccine in older adults
-
- Journal Article
- A1
- open access
Double-blind, placebo-controlled, dose-escalating study evaluating the safety and immunogenicity of an epitope-specific chemically defined nanoparticle RSV vaccine
-
- Journal Article
- A1
- open access
Practice testing of generic quality indicators for responsible antibiotic use in nine hospitals in the Dutch–Belgian border area
-
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial
-
- Journal Article
- A1
- open access
A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
-
- Journal Article
- A1
- open access
The role of cell-mediated immunity against influenza and its implications for vaccine evaluation
-
- Journal Article
- A1
- open access
Randomized, double-blind, reference-controlled, phase 2a study evaluating the immunogenicity and safety of OVX836, a nucleoprotein-based influenza vaccine
-
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD) : a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial